S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

NGM Biopharmaceuticals Stock Forecast, Price & News

-0.61 (-3.26%)
(As of 12/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
242,778 shs
Average Volume
347,727 shs
Market Capitalization
$1.40 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive NGM News and Ratings via Email

Sign-up to receive the latest news and ratings for NGM Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

NGM Biopharmaceuticals logo

About NGM Biopharmaceuticals

NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases. Its lead product candidate, aldafermin, is designed for the treatment of patients with non-alcoholic steatohepatitis, with liver fibrosis stage 2, 3, or 4. The company was founded by Jin-Long Chen on December 20, 2007 and is headquartered in South San Francisco, CA.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$87.37 million
Book Value
$4.58 per share


Net Income
$-102.49 million
Net Margins
Pretax Margin




Free Float
Market Cap
$1.40 billion

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.38 out of 5 stars

Medical Sector

209th out of 1,390 stocks

Pharmaceutical Preparations Industry

83rd out of 668 stocks

Analyst Opinion: 3.6Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -

NGM Biopharmaceuticals (NASDAQ:NGM) Frequently Asked Questions

Is NGM Biopharmaceuticals a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NGM Biopharmaceuticals in the last twelve months. There are currently 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" NGM Biopharmaceuticals stock.
View analyst ratings for NGM Biopharmaceuticals
or view top-rated stocks.

How has NGM Biopharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

NGM Biopharmaceuticals' stock was trading at $15.35 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NGM shares have increased by 18.0% and is now trading at $18.11.
View which stocks have been most impacted by COVID-19

When is NGM Biopharmaceuticals' next earnings date?

NGM Biopharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022.
View our earnings forecast for NGM Biopharmaceuticals

How were NGM Biopharmaceuticals' earnings last quarter?

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) announced its quarterly earnings data on Thursday, November, 4th. The company reported ($0.37) EPS for the quarter, missing the Zacks' consensus estimate of ($0.34) by $0.03. NGM Biopharmaceuticals had a negative trailing twelve-month return on equity of 34.43% and a negative net margin of 157.90%.
View NGM Biopharmaceuticals' earnings history

What price target have analysts set for NGM?

8 brokers have issued 1 year price targets for NGM Biopharmaceuticals' stock. Their forecasts range from $22.00 to $44.00. On average, they anticipate NGM Biopharmaceuticals' share price to reach $35.78 in the next year. This suggests a possible upside of 97.6% from the stock's current price.
View analysts' price targets for NGM Biopharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are NGM Biopharmaceuticals' key executives?

NGM Biopharmaceuticals' management team includes the following people:
  • David J. Woodhouse, Chief Executive Officer & Director
  • Siobhan Nolan Mangini, CFO & Principal Accounting Officer
  • Jin-Long Chen, Director & Chief Scientific Officer
  • Hui Tian, Vice President-Research
  • Marc Learned, Vice President-Research Operations

What is David Woodhouse's approval rating as NGM Biopharmaceuticals' CEO?

3 employees have rated NGM Biopharmaceuticals CEO David Woodhouse on Glassdoor.com. David Woodhouse has an approval rating of 34% among NGM Biopharmaceuticals' employees. This puts David Woodhouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

When did NGM Biopharmaceuticals IPO?

(NGM) raised $100 million in an IPO on Thursday, April 4th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Cowen acted as the underwriters for the IPO.

What is NGM Biopharmaceuticals' stock symbol?

NGM Biopharmaceuticals trades on the NASDAQ under the ticker symbol "NGM."

Who are NGM Biopharmaceuticals' major shareholders?

NGM Biopharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.16%), StepStone Group LP (2.03%), Point72 Asset Management L.P. (1.87%), Geode Capital Management LLC (0.83%), AXA S.A. (0.52%) and Hennion & Walsh Asset Management Inc. (0.36%). Company insiders that own NGM Biopharmaceuticals stock include David J Woodhouse, Group L P Column, Hsiao D Lieu, Hsiao D Lieu, Jin-Long Chen and Peter Svennilson.
View institutional ownership trends for NGM Biopharmaceuticals

Which institutional investors are selling NGM Biopharmaceuticals stock?

NGM stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, SG Americas Securities LLC, Hennion & Walsh Asset Management Inc., Strs Ohio, Nisa Investment Advisors LLC, Squarepoint Ops LLC, New York State Common Retirement Fund, and Lord Abbett & CO. LLC. Company insiders that have sold NGM Biopharmaceuticals company stock in the last year include David J Woodhouse, Hsiao D Lieu, and Jin-Long Chen.
View insider buying and selling activity for NGM Biopharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying NGM Biopharmaceuticals stock?

NGM stock was purchased by a variety of institutional investors in the last quarter, including StepStone Group LP, Point72 Asset Management L.P., Two Sigma Investments LP, Goldman Sachs Group Inc., BlackRock Inc., Citigroup Inc., Two Sigma Advisers LP, and Dimensional Fund Advisors LP. Company insiders that have bought NGM Biopharmaceuticals stock in the last two years include Group L P Column, and Peter Svennilson.
View insider buying and selling activity for NGM Biopharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of NGM Biopharmaceuticals?

Shares of NGM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NGM Biopharmaceuticals' stock price today?

One share of NGM stock can currently be purchased for approximately $18.11.

How much money does NGM Biopharmaceuticals make?

NGM Biopharmaceuticals has a market capitalization of $1.40 billion and generates $87.37 million in revenue each year. The company earns $-102.49 million in net income (profit) each year or ($1.61) on an earnings per share basis.

How many employees does NGM Biopharmaceuticals have?

NGM Biopharmaceuticals employs 210 workers across the globe.

What is NGM Biopharmaceuticals' official website?

The official website for NGM Biopharmaceuticals is www.ngmbio.com.

Where are NGM Biopharmaceuticals' headquarters?

NGM Biopharmaceuticals is headquartered at 333 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA, 94080.

How can I contact NGM Biopharmaceuticals?

NGM Biopharmaceuticals' mailing address is 333 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (650) 243-5555 or via email at [email protected].

This page was last updated on 12/4/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.